ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Induction in the Elderly: A Comparison of Basiliximab versus Rabbit Anti-Thymocyte Globulin After Kidney Transplantation.

J. Lee, E. Liu, M. Aull, S. Kapur.

Weill Cornell Medical Center, New York, NY

Meeting: 2017 American Transplant Congress

Abstract number: B185

Keywords: Elderly patients, Induction therapy, Kidney transplantation

Session Information

Date: Sunday, April 30, 2017

Session Name: Poster Session B: Kidney Immunosuppression: Induction Therapy

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall D1

Related Abstracts
  • Kidney Patients at High Immunological Risk Can Be Safely Transplanted With a Novel Induction Regimen Using Anti-Thymocyte Globulin (Rabbit) (rATG) Plus Basiliximab
  • Preliminary Results of a Novel Induction Regimen Using Anti-Thymocyte Globulin (Rabbit) (rATG) Plus Basiliximab in a Pediatric Patient Population Undergoing Kidney Transplantation

Background: Although it is well established that kidney transplant (KT) in the elderly is beneficial and safe, there is limited literature on the appropriate choice of induction agent in this population. Therefore, we wanted to determine if there were differences in outcomes between basiliximab and anti-thymocyte globulin (ATG) induction after KT following a steroid-sparing immunosuppression regimen in patients 65 years of age and older.

Methods: This study was a single-center, retrospective cohort study of all elderly patients who received a KT at our center between January 1, 2010 and December 31, 2015 who received either basiliximab or ATG. Patients were excluded if they received both agents as induction during their admission or were maintained on steroids after KT. The co-primary outcomes of this study were patient and graft survival. The secondary outcomes included incidence of acute rejection, infection, neutropenia, and malignancy.

Results: A total of 238 patients were included in the study of which 68 patients (29%) received basiliximab induction. More patients in the basiliximab group were older, dialysis dependent prior to transplant, had a history of prior transplants, and experienced delayed graft function. There was no statistical difference in graft loss and patient deaths between the two groups, p=0.53 and 0.08, respectively. Additionally, there was no difference in the incidence of acute rejection, neutropenia, and malignancy. Of the infections however, more patients in the basiliximab group developed pneumonia compared to patients in the ATG group.Conclusion: There were no significantly different outcomes in elderly KT recipients between the two induction strategies except for increased incidence of pneumonia in patients that received basiliximab.

CITATION INFORMATION: Lee J, Liu E, Aull M, Kapur S. Induction in the Elderly: A Comparison of Basiliximab versus Rabbit Anti-Thymocyte Globulin After Kidney Transplantation. Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Lee J, Liu E, Aull M, Kapur S. Induction in the Elderly: A Comparison of Basiliximab versus Rabbit Anti-Thymocyte Globulin After Kidney Transplantation. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/induction-in-the-elderly-a-comparison-of-basiliximab-versus-rabbit-anti-thymocyte-globulin-after-kidney-transplantation/. Accessed April 23, 2021.

« Back to 2017 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.